Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high-affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma, inadequately controlled by high doses of standard inhaled treatments.
Ayres, J.G. , Higgins, B. , Chilvers, E.R. , Ayre, G. , Blogg, M. and Fox, H. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma . Allergy59: 701-708.
2.
Bargagli, E. , Madioni, C. , Olivieri, C. , Penza, F. and Rottoli, P. (2008) Churg-Strauss vasculitis in a patient treated with omalizumab . J Asthma45: 115-116.
3.
Barnes, P.J. (2008) Immunology of asthma and chronic obstructive pulmonary disease . Nat Rev Immunol8: 183-192.
4.
Bateman, E.D. , Boushey, H.A. , Bousquet, J. , Busse, W.W. , Clark, T.J. , Pauwels, R.A. et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL (GOAL) study . Am J Respir Crit Care Med170: 836-844.
5.
Bousquet, J. , Rabe, K. , Humbert, M. , Chung, K.F. , Berger, W. , Fox, H. et al. (2007) Predicting and evaluating response to omalizumab in patients with severe allergic asthma . Respir Med101: 1483-1492.
6.
Brown, R. , Turk, F. , Dale, P. and Bousquet, J. (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma . Allergy62: 149-153.
7.
Busse, W. , Corren, J. , Lanier, B.Q. , McAlary, M. , Fowler-Taylor, A. , Cioppa, G.D. et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthma . J Allergy Clin Immunol108: 184-190.
8.
Carlsson, F. , Hjelm, F. , Conrad, D.H. and Heyman, B. (2007) IgE enhances specific antibody and T cell responses in mice over-expressing CD23 . Scand J Immunol66: 261-270.
9.
Casale, T.B. , Condemi, J. , LaForce, C. , Nayak, A. , Rowe, M. , Watrous, M. et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis. A randomised controlled trial . JAMA286: 2956-2967.
10.
Chang, T.W. (2000) The pharmacological basis of anti-IgE therapy . Nat Biotechnol18: 157-162.
11.
Chang, T.W. , Wu, P.C. , Hsu, C.L. and Hung, A.F. (2007) Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases . Adv Immunol93: 63-119.
12.
Cooper, P.J. , Ayre, G. , Martin, C. , Rizzo, J.A. , Ponte, E.V. and Cruz, A.A. (2008) Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment . Allergy63: 409-418.
13.
Corren, J. , Shapiro, G. , Reimann, J. , Deniz, Y. , Wong, D. , Adelman, D. et al. (2008) Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy . J Allergy Clin Immunol121: 506-511.
14.
Cox, L. , Platts-Mills, T.A.E. , Finegold, I. , Schwartz, L.B. , Simons, F.E.R. and Wallace, D.V. (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis . J Allergy Clin Immunol120: 1373-1377.
15.
Cruz, A.A. , Lima, F. , Sarinho, E. , Ayre, G. , Martin, C. , Fox, H. et al. (2007) Safety on anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infections . Clin Exp Allergy37: 197-207.
16.
D'Amato, G. (2006) Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases . Eur J Pharmacol533: 302-307.
17.
D'Amato, G. , Salzillo, A. , Piccolo, A. , D'Amato, M. and Liccardi, G. (2007) A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma . Ther Clin Risk Managem3: 613-619.
18.
Djukanovic, R. , Wilson, S.J. , Kraft, M. , Jarjour, N.N. , Steel, M. , Chung, K.F. et al. (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma . Am J Respir Crit Care Med170: 583-593.
19.
Dolan, C.M. , Fraher, K.E. , Bleecker, E.R. , Borish, L. , Chipps, B. , Hayden, M.L. et al. (2004) Design of baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma . Ann Allergy Asthma Immunol92: 32-39.
20.
ENFUMOSA (European Network for Understanding Mechanisms of Severe Asthma) Study Group) (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma . Eur Respir J22: 470-477.
21.
Fahy, J.V. , Fleming, H.E. , Wong, H.H. , Liu, J.T. , Su, J.Q. , Reimann, J. et al. (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects . Am J Respir Crit Care Med155: 1828-1834.
22.
Fox, J.A. , Hotaling, T.E. , Struble, C. , Ruppel, J. , Bates, D.J. and Schoenhoff, M.B. (1996) Tissue distribution and complex generation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys . J Pharmacol Exp Ther279: 1000-1008.
23.
Giavina-Bianchi, P. , Gravina-Bianchi, M. , Agoni, R. and Kalil, J. (2008) Omalizumab and Churg-Strauss syndrome . J Allergy Clin Immunol122: 217 .
24.
Global Initiative for Asthma (GINA) (2006) Global strategy for asthma management and prevention. Available at: http://www.ginasthma.org..
25.
Gould, H.J. and Sutton, B.J. (2008) IgE in allergy and asthma today . Nat Rev Immunol8: 205-217.
26.
Hanania, A. (2008) Targeting airway inflammation in asthma: current and future therapies . Chest133: 989-998.
27.
Hartert, T.V. and Peebles Jr., R.S. (2000) Epidemiology of asthma: the year in review . Curr Opin Pulm Med6: 4-9.
28.
Haselkorn, T. , Borish, L. , Miller, D.P. , Weiss, S.T. and Wong, D.A. (2006) High prevalence of skin test positivity in severe or difficult-to-treat asthma . J Asthma43: 745-752.
29.
Hendeles, L. and Sorkness, C.A. (2007) Anti-immunoglobulin E therapy with omalizumab for asthma . Ann Pharmacother41: 1397-1410.
30.
Hochhaus, G. , Brookman, L. , Fox, H. , Johnson, C. , Matthews, J. , Ren, S. et al. (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategy and clinical efficacy in the treatment of allergic asthma . Curr Med Res Opin19: 491-498.
Holgate, S.T. , Chuchalin, A.G. , Hebert, J. , Lotvall, J. , Persson, G.B. , Chung, K.F. et al. (2004) Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma . Clin Exp Allergy36: 632-638.
33.
Holgate, S. , Casale, T. , Wenzel, S. , Bousquet, J. , Deniz, Y. and Reisner, C. (2005a) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation . J Allergy Clin Immunol115: 459-465.
34.
Holgate, S.T. , Djukanovic, R. , Casale, T. and Bousquet, J. (2005b) Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy . Clin Exp Allergy35: 408-416.
35.
Holgate, S.T. and Polosa, R. (2008) Treatment strategies for allergy and asthma . Nat Rev Immunol8: 218-230.
36.
Humbert, M. , Beasley, R. , Ayres, J. , Slavin, R. , Hebert, J. , Bousquet, J. et al. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE . Allergy60: 309-316.
37.
Humbert, M. , Berger, W. , Rapatz, G. and Turk, F. (2008) Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent asthma . Allergy63: 592-596.
38.
Kitamura, K. , Takeda, K. , Koya, T. , Miyahara, N. , Kodama, T. , Dakhama, A. et al. (2007) Critical role of the Fc receptor [gamma]-chain on APCs in the development of allergen-induced airway hyper-responsiveness and inflammation . J Immunol178: 480-488.
39.
Kitaura, J. , Song, J. , Tsai, M. , Asai, K. , Maeda-Yamamoto, M. , Mocsai, A. et al. (2003) Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI . Proc Natl Acad Sci USA100: 12911-12916.
40.
Lang, D.M. (2007) An overview of EPR3 asthma guidelines: what's different? . Allergy Asthma Proc28: 620-627.
41.
Lanier, B.Q. (2003) Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE . Ann Allergy Asthma Immunol90: 13-15.
42.
Lanier, B.Q. , Corren, J. , Lumry, W. , Liu, J. , Fowler-Taylor, A. and Gupta, N. (2003) Omalizumab is effective in the long-term control of severe allergic asthma . Ann Allergy Asthma Immunol91: 154-159.
43.
Lanier, B.Q. and Chang, T.W. (2004) Will anti-IgE therapy compromise normal immune functions? . Allergy Clin Immunol Int: J World Allergy Org16: 237-240.
44.
Larché, M. , Robinson, D.S. and Kay, A.B. (2003) The role of T lymphocytes in the pathogenesis of asthma . J Allergy Clin Immunol111: 450-463.
45.
Marcus, P. (2006) Incorporating anti-IgE (omalizumab) therapy in clinical practice: practice management implications . Chest129: 466-474.
46.
Masoli, M. , Fabian, D. , Holt, S. and Beasley, R. (2004) The global burden of asthma: executive summary of the GINA dissemination committee report . Allergy59: 469-478.
47.
McDanel, D.L. and Muller, B.A. (2005) The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction ? Ther Clin Risk Manag1: 125-140.
48.
Miller, C.W.T. , Krishnaswamy, N. , Johnston, C. and Krishnaswamy, G. (2008) Severe asthma and the omalizumab option . Clin Mol Allergy6: 4 .
49.
Molimard, M. , de Blay, F. , Didier, A. and Le Gros, V. (2008) Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France . Respir Med102: 71-76.
50.
National Health Interview Survey (2003- 2005) Asthma prevalence, health care use, and mortality: United States, 2003-05. National Center for Health Statistics . Available at: http://www.cdc.gov/nhcs/products/pubs/pubd/hestats/asthma03-05/asthma03-05.htm
51.
Niven, R. , Chung, K.F. , Panahloo, Z. , Blogg, M. and Ayre, G. (2008) Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study . Respir Med102: 1371-1378.
Noga, O. , Hanf, G. and Kunkel, G. (2003) Immunological and clinical changes in allergic asthmatics following treatment with omalizumab . Int Arch Allergy Immunol131: 46-52.
54.
Noga, O. , Hanf, G. , Brachmann, I. , Klucken, A.C. , Kleine-Tebbe, J. , Rosseau, S. et al. (2006) Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma . J Allergy Clin Immunol117: 1493-1499.
55.
Nopp, A. , Johansson, S.G.O. , Ankerst, J. , Palmqvist, M. and Oman, H. (2007) CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment . Allergy62: 1175-1181.
56.
Pabst, S. , Tiyerili, V. and Grohé, C. (2008) Apparent response to anti-IgE therapy in two patients with refractory 'forme fruste' of Churg-Strauss syndrome . Thorax63: 747-748.
57.
Parks, K.W. and Casale, T.B. (2006) Anti-immunoglobulin E monoclonal antibody administered with immunotherapy . Allergy Asthma Proc27: S33-S36.
58.
Pascual, R.M. and Peters, S.P. (2005) Airway remodeling contributes to the progressive loss of lung function in asthma: an overview . J Allergy Clin Immunol116: 477-486.
59.
Pelaia, G. , Vatrella, A. , Calabrese, C. , Mazzarella, G. and Marsico, S.A. (2000) New perspectives in asthma treatment . Allergy55(Suppl. 61): 60-66.
60.
Presta, L.G. , Lahr, S.J. , Shields, R.L. , Porter, J.P. , Gorman, C.M. , Fendly, B.M. et al. (1993) Humanization of an antibody directed against IgE . J Immunol151: 2623-2632.
61.
Presta, L. , Shields, R. , O'Connell, L. , Lahr, S. , Porter, J. , Gorman, C. et al. (1994) . The binding site of a human immunoglobulin E for its high affinity receptor . J Biol Chem269: 26368-26373.
62.
Price, D. (2008) The use of omalizumab in asthma . Prim Care Respir J17: 62-72.
63.
Price, K.S. and Hamilton, R.G. (2007) Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy . Allergy Asthma Proc28: 313-319.
64.
Prieto, L. , Gutiérrez, V. , Colas, C. , Tabar, A. , Pérez-Francés, C. , Bruno, L. et al. (2006) Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma . Int Arch Allergy Immunol139: 122-131.
65.
Puéchal, X. , Rivereau, P. and Vinchon, F. (2008) Churg-Strauss syndrome associated with omalizumab . Eur J Intern Med19: 364-366.
66.
Ruppert, A.M. , Averous, G. , Stanciu, D. , Deroide, N. , Riehm, S. , Poindron, V. et al. (2008) Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment . J Allergy Clin Immunol121: 253-254.
67.
Saini, S.S. , MacGlashan Jr., D.W. , Sterbinsky, S.A. , Togias, A. , Adelman, D.C. , Lichtenstein, L.M. et al. (1999) Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE infusions is reversible in vitro and in vivo . J Immunol162: 5624-5639.
68.
Silkoff, P.E. , Romeo, F.A. , Gupta, N. , Townley, R.G. and Milgrom, H. (2004) Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody . Pediatrics113: e308-e312.
69.
Solér, M. , Matz, J. , Townley, R. , Buhl, R. , O'Brien, J. , Fox, H. et al. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics . Eur Respir J18: 254-261.
70.
Spector, S. (2004) Omalizumab efficacy in allergic disease . Panminerva Med46: 141-148.
71.
Sullivan, S.D. and Turk, F. (2008) An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma . Allergy63: 670-684.
72.
Tarantini, F. , Baiardini, I. , Passalacqua, G. , Braido, F. and Canonica, GW (2007) Asthma treatment: 'magic bullets which seek their own targets' . Allergy62: 605-610.
73.
Taylor, D.R. , Bateman, E.D. , Boulet, L.P. , Boushey, H.A. , Busse, W.W. , Casale, T.B. et al. (2008) A new perspective on concepts of asthma severity and control . Eur Respir J32: 545-554.
74.
Verbruggen, K. , Van Cauwenberge, P. and Bachert, C.(2009) Anti-IgE for the treatment of allergic rhinitis - and eventually nasal polyps? . Int Arch Allergy Immunol148: 87-98.
75.
Vignola, A.M. , Humbert, M. , Bousquet, J. , Boulet, L.P. , Hedgecock, S. , Blogg, M. et al. (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR . Allergy59: 709-717.
76.
Wenzel, S.E. , Fahy, J.V. , Irvin, C.G. , Peters, S.P. , Spector, S. and Szefler, S.J. (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations and unanswered questions . Am J Respir Crit Care Med162: 2341-2351.
77.
Wenzel, S.E. and Busse, W.W. (2007) Severe asthma: lessons from the severe asthma research program . J Allergy Clin Immunol119: 14-21.
78.
Winchester, D.E. (2006) Omalizumab for asthma . N Engl J Med355: 1281-1282.
